Overslaan en naar de inhoud gaan
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NL
FR
EN
PT
NL
NB
DE
IT
Home
Company Press Releases
Company press releases
Subscribe
Filters
Filters
Verversen
Herstel
Icon After
Datum
Omschakelen Zichtbaarheid
All
Vandaag
Deze week
This month
Custom date range
From
To
Topic
Omschakelen Zichtbaarheid
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Omschakelen Zichtbaarheid
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 101 - 138 of 138 results
Released
Company
Title
Industry
Topic
22 Mar 2022
07:35 CET
VALBIOTIS
Valbiotis renforce son engagement dans la RSE en adhérant au Global Compact des Nations Unies et en appliquant la norme ISO 26000
20103010 Biotechnology
Corporate life
22 Mar 2022
07:35 CET
VALBIOTIS
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
20103010 Biotechnology
Corporate life
15 Mar 2022
17:40 CET
VALBIOTIS
Valbiotis Publishes Its 2021 Annual Report
20103010 Biotechnology
Commercial results
15 Mar 2022
17:40 CET
VALBIOTIS
Valbiotis publie ses résultats annuels 2021
20103010 Biotechnology
Commercial results
03 Mar 2022
18:00 CET
VALBIOTIS
Valbiotis Announces Upcoming Organizational Changes of its Board of Directors
20103010 Biotechnology
Corporate life
03 Mar 2022
18:00 CET
VALBIOTIS
Valbiotis annonce une évolution prochaine de son Directoire
20103010 Biotechnology
Corporate life
24 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis Presents Its 2022 Financial Communication Calendar
20103010 Biotechnology
Other subject
24 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis publie son calendrier financier 2022
20103010 Biotechnology
Other subject
17 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure
20103010 Biotechnology
Products and services
17 Feb 2022
07:35 CET
VALBIOTIS
Valbiotis annonce avoir reçu les autorisations de lancer les deux études cliniques de Phase II/III INSIGHT et INSIGHT 2, dernière étape du développement de TOTUM•854 pour la réduction de la pression artérielle
20103010 Biotechnology
Products and services
28 Jan 2022
17:40 CET
VALBIOTIS
Valbiotis : Bilan semestriel du contrat de liquidité
20103010 Biotechnology
Other subject
06 Jan 2022
07:35 CET
VALBIOTIS
Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
20103010 Biotechnology
Other subject
06 Jan 2022
07:35 CET
VALBIOTIS
Valbiotis - Accélération du calendrier clinique sur des indications majeures : des résultats attendus en 2022 dans le prédiabète, l’hypercholestérolémie et la pression artérielle
20103010 Biotechnology
Other subject
01 Dec 2021
07:35 CET
VALBIOTIS
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
20103010 Biotechnology
Other subject
01 Dec 2021
07:35 CET
VALBIOTIS
Valbiotis annonce avoir soumis aux autorités compétentes les trois protocoles cliniques pour TOTUM•854 indiqué dans la réduction de la pression artérielle et présente son plan de développement clinique complet
20103010 Biotechnology
Other subject
15 Nov 2021
07:35 CET
VALBIOTIS
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
20103010 Biotechnology
Other subject
15 Nov 2021
07:35 CET
VALBIOTIS
Valbiotis annonce des résultats précliniques positifs de TOTUM•070 contre l’hypercholestérolémie, sélectionnés et présentés au congrès annuel de l’American Heart Association (AHA)
20103010 Biotechnology
Other subject
30 Sep 2021
07:38 CEST
VALBIOTIS
Rapport financier semestriel 2021
20103010 Biotechnology
Corporate life
30 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021
20103010 Biotechnology
Other subject
30 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis fait le point sur ses activités et publie son rapport financier pour le premier semestre 2021
20103010 Biotechnology
Other subject
24 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
20103010 Biotechnology
Other subject
24 Sep 2021
07:35 CEST
VALBIOTIS
Valbiotis consolide son développement de solutions de santé naturelles innovantes en intégrant l'exploration de micro-algues produites en Nouvelle-Calédonie, au travers d'un accord exclusif avec l’ADECAL-Technopole et l’IFREMER
20103010 Biotechnology
Other subject
09 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis Releases its Letter to Shareholders for 2021
20103010 Biotechnology
Other subject
09 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis publie sa Lettre aux actionnaires 2021
20103010 Biotechnology
Other subject
06 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis annonce la fin du recrutement de l’étude clinique de Phase II HEART conduite avec TOTUM•070 contre l’hypercholestérolémie, facteur de risque des maladies cardiovasculaires
20103010 Biotechnology
Other subject
06 Sep 2021
17:40 CEST
VALBIOTIS
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
20103010 Biotechnology
Other subject
28 Jul 2021
07:45 CEST
VALBIOTIS
Document d'enregistrement universel
20103010 Biotechnology
Corporate life
27 Jul 2021
21:39 CEST
VALBIOTIS
Valbiotis : Mise à disposition du Document d’enregistrement universel
20103010 Biotechnology
Other subject
22 Jul 2021
17:40 CEST
VALBIOTIS
Valbiotis : Bilan semestriel du contrat de liquidité
20103010 Biotechnology
Other subject
28 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
20103010 Biotechnology
New
28 Jun 2021
17:40 CEST
VALBIOTIS
Valbiotis annonce la réalisation de l’étude clinique de mode d’action sur TOTUM•63 par l’INAF1 de l’Université Laval à Québec, en partenariat avec Nestlé Health Science
20103010 Biotechnology
New
28 Oct 2020
07:43 CET
VALBIOTIS
Rapport financier semestriel 2020
20103010 Biotechnology
Legal
26 Oct 2018
15:38 CEST
VALBIOTIS
Rapport financier semestriel 30 juin 2018
Biotechnology
-
26 Oct 2018
15:37 CEST
VALBIOTIS
Rapport financier annuel 31 décembre 2017
Biotechnology
Corporate life
24 Jul 2018
15:51 CEST
VALBIOTIS
Bilan semestriel du contrat de liquidité confié à la société Portzamparc
Biotechnology
-
31 Jan 2018
18:14 CET
VALBIOTIS
Bilan semestriel du contrat de liquidité VALBIOTIS confié à la société PORTZAMPARC
Biotechnology
-
29 Sep 2017
07:36 CEST
VALBIOTIS
Rapport financier semestriel au 30 juin 2017
Biotechnology
Income
06 Jul 2017
19:05 CEST
VALBIOTIS
Bilan semestriel du contrat de liquidité VALBIOTIS confié à la société PORTZAMPARC
Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Paginering
«
« First
‹
‹‹
1
2
3
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Markten
Amsterdam
Cash Producten
Aandelen
AEX index Stocks
AEX ESG Stocks
Indices
Beleggingsfondsen
Obligaties
ETFs
Gestructureerde producten
Derivaten
Indexopties
Indexfutures
Aandelenopties
Dividend derivativen
Aandelenfutures
Quote Vendor Codes
Company regulated news
Latest
Archive
Euronext Brussel
Cash Producten
Aandelen
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Obligaties
ETFs
Gestructureerde producten
Derivaten
Indexfutures
Aandelenopties
Aandelenfutures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Euronext Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Euronext Lissabon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Euronext Parijs
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Aandelen
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Beleggingsfondsen
Directory
ESG Funds
Oslo Mutual Funds
Obligaties
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Gestructureerde producten
Directory / search
Handel tijdens een Bid-Only situatie
Turbo handel in Nederland
Aandelen en FX-derivaten
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Commodities
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Trading calendars
Delivery
Wholesale Trading
Commitments of Traders (CoT) report
Contracts specifications
Quote vendor codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Hulpmiddelen
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Waar vind ik?